methotrexate mtx formerly known amethopterin chemotherapy agent immunesystem used treat cancer autoimmune diseases ectopic types cancers used include breast cancer leukemia lung cancer lymphoma gestational trophoblastic disease types autoimmune diseases used include psoriasis rheumatoid arthritis crohns given mouth common side effects include nausea feeling tired fever increased risk infection low white blood cell counts breakdown skin inside side effects may include liver disease lung disease lymphoma severe skin people longterm treatment regularly checked side safe kidney problems lower doses may acts blocking bodys use folic methotrexate first made initially used treat cancer less toxic thencurrent provided first cures metastatic world health organizations list essential methotrexate available generic commonly prescribed medication united states million methotrexate originally developed continues used chemotherapy either alone combination agents effective treatment number cancers including solid tumours breast head neck lung bladder well acute lymphocytic leukemias nonhodgkins lymphoma osteosarcoma choriocarcinoma trophoblastic although originally designed chemotherapy drug lower doses methotrexate generally safe welltolerated drug treatment certain autoimmune diseases methotrexate used diseasemodifying treatment number autoimmune diseases adults including rheumatoid psoriasis psoriatic arthritis reactive arthritis enteropathic arthritis myositis systemic sclerosis lupus sarcoidosis crohns eczema many forms vasculitis children used juvenile dermatomyositis juvenile idiopathic arthritis uveitis localised methotrexate one firstline therapies treatment rheumatoid arthritis weekly doses found cochrane review beneficial weeks duration therapy though used longerterm clinical practice discontinuation rates high due adverse use low doses methotrexate together nsaids aspirin analgesics paracetamol relatively safe people treated rheumatoid arthritis appropriate methotrexate also sometimes used combination conventional dmards sulfasalazine studies reviews found rheumatoid arthritis patients treated methotrexate one year less pain functioned better fewer swollen tender joints less disease activity overall reported doctorscitation needed xrays also showed progress disease slowed stopped many people receiving methotrexate progression completely halted receiving individuals rheumatoid arthritis treated methotrexate found lower risk cardiovascular events myocardial infarctions results systematic review exploring comparative effectiveness treatments early rheumatoid arthritis show treatment efficacy improved combination therapy antitnf biologic medications compared methotrexate likewise study found use methotrexate combination antitnf agents shown effective treatment ulcerative methotrexate also used multiple used occasionally systemic lupus erythematosus tentative evidence support methotrexate abortifacient used treat ectopic pregnancies provided fallopian tube methotrexate dilation curettage used treat molar pregnancy rarely used combination mifepristone abort uterine methotrexate given mouth injection intramuscular intravenous subcutaneous doses usually taken weekly daily limit routine monitoring complete blood count liver function tests creatinine measurements creatinine recommended least every two folic acid commonly coprescribed methotrexate minimise risk adverse common adverse effects include hepatotoxicity stomatitis blood abnormalities leukopenia anaemia thromboycytopenia increased risk infection hair loss nausea reduced appetite abdominal pain diarrhoea fatigue fever dizziness drowsiness headache acute pneumonitis renal methotrexate also cause methotrexate pneumonitis rare complication therapy appears reducing frequency recent rheumatoid arthritis treatment context rheumatoid arthritis interstitial lung disease methotrexate treatment may associated lower incidence ild timecitation needed methotrexate teratogenic advised stop taking least weeks becoming pregnant avoided pregnancy pregnancy category x guidelines updated state safe male partner take point trying central nervous system reactions methotrexate reported especially given via intrathecal route directly cerebrospinal fluid include myelopathies leukoencephalopathies variety cutaneous side effects particularly administered high another little understood serious possible adverse effect methotrexate neurological damage memory neurotoxicity may result drug crossing barrier damaging neurons cerebral cortex people cancer receive medication often nickname effects chemo brain chemo penicillins may decrease elimination methotrexate increase risk may used together increased monitoring aminoglycosides neomycin paromomycin found reduce gastrointestinal gi absorption probenecid inhibits methotrexate excretion increases risk methotrexate likewise retinoids trimethoprim known interact methotrexate produce additive hepatotoxicity haematotoxicity immunosuppressants like cyclosporins may potentiate methotrexates haematologic effects hence potentially leading nsaids also found fatally interact methotrexate numerous case nitrous oxide potentiating haematological toxicity methotrexate also protonpump inhibitors omeprazole anticonvulsant valproate found increase plasma concentrations methotrexate nephrotoxic agents cisplatin gi drug colestyramine methotrexate antimetabolite antifolate type thought affect cancer rheumatoid arthritis two different pathways cancer methotrexate competitively inhibits dihydrofolate reductase dhfr enzyme participates tetrahydrofolate affinity methotrexate dhfr dihydrofolate dhfr catalyses conversion dihydrofolate active tetrahydrofolate needed de novo synthesis nucleoside thymidine required dna also folate essential purine pyrimidine base biosynthesis synthesis inhibited methotrexate therefore inhibits synthesis dna rna thymidylates treatment rheumatoid arthritis inhibition dhfr thought main mechanism rather multiple mechanisms appear involved including inhibition enzymes involved purine metabolism leading accumulation adenosine inhibition cell activation suppression intercellular adhesion molecule expression cells selective downregulation b cells increasing sensitivity activated cells inhibition methyltransferase activity leading deactivation enzyme activity relevant immune system another mechanism mtx inhibition binding interleukin cell surface thereby acts anticytokine team researchers led sidney farber showed aminopterin chemical analogue folic acid developed yellapragada subbarao lederle could induce remission children acute lymphoblastic leukemia development folic acid analogues prompted discovery administration folic acid worsened leukemia diet deficient folic acid could conversely produce improvement mechanism action behind effects still unknown analogues folic acid development methotrexate known amethopterin proposed treatment animal studies published showed therapeutic index methotrexate better aminopterin clinical use aminopterin thus abandoned favor methotrexatecitation needed jane c wright demonstrated use methotrexate solid tumors showing remission breast wrights group first demonstrate use drug solid tumors opposed leukemias cancer marrow min chiu li collaborators demonstrated complete remission women choriocarcinoma chorioadenoma wright et al produced remissions mycosis httpsenwikipediaorgwikimethotrexate